Dr. Mehta Discusses Combinations in Multiple Myeloma

Video

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

In relapsed disease, it has been concluded that 3-drug regimens are better than 2-drug combinations. But, whether they are truly better in patients who may or may not undergo transplant is unclear, says Mehta.

This poses the question of giving more drugs upfront, or introducing drugs later in the disease course. Adding more drugs also brings up the question of cost.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Annie Im, MD, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology